Search results
AbbVie's (ABBV) Skyrizi Gets FDA Nod for Crohn's Disease
Zacks via Yahoo Finance· 2 years agoThe FDA approval of AbbVie's (ABBV) Skyrizi for moderately to severely active Crohn's disease was...
Pharma Stock Roundup: MRK to Buy IMGO, ABBV's Skyrizi Gets EU Nod for New Indication
Zacks via Yahoo Finance· 1 year agoThis week, Merck MRK offered to buy Imago Biosciences IMGO, which is developing drugs to treat bone...
Pharma Stock Roundup: FDA OK's Expanded Use of ABBV, MRK, NVS Drugs, Other Updates
Zacks via Yahoo Finance· 2 years agoThe FDA approves expanded use of AbbVie's (ABBV) Skyrizi, Merck's (MRK) Vaxneuvance vaccine and...
Can AbbVie's (ABBV) New Drugs Make up for Lost Humira Sales?
Zacks via Yahoo Finance· 2 years agoAbbVie's (ABBV) new drugs, Skyrizi and Rinvoq, are faring well, bolstered by approval in new...
Can AbbVie (ABBV) Protect Revenues After Humira Patent Loss?
Zacks via Yahoo Finance· 8 months agoAbbVie’s ABBV key blockbuster immunology medicine, Humira lost patent protection in the United...
AbbVie (ABBV) Q2 2022 Earnings Call Transcript
Motley Fool· 2 years agoImage source: The Motley Fool. AbbVie (NYSE: ABBV) Q2 2022 Earnings Call Jul 29, 2022, 9:00 a.m. ET Contents: Prepared Remarks Questions and Answers Call...
Here's What's Driving AbbVie's (ABBV) Outperformance This Year
Zacks via Yahoo Finance· 1 year agoAbbVie (ABBV) boasts several new drugs with the potential to drive revenues once Humira loses U.S....
The Zacks Analyst Blog Highlights AbbVie, J&J, Eli Lilly, Pfizer
Zacks via Yahoo Finance· 5 months agoFor Immediate Release Chicago, IL – November 30, 2023 – Zacks.com announces the list of stocks...
AbbVie's (ABBV) Rinvoq Gets CHMP Nod for New Indication
Zacks via Yahoo Finance· 2 years agoAbbVie Inc. ABBV announced that the European Medicines Agency’s Committee for Medicinal Products for...
AbbVie (ABBV) to Report Q2 Earnings: What's in the Cards?
Zacks via Yahoo Finance· 9 months agoAbbVie's (ABBV) Q2 performance will likely reflect Skyrizi and Rinvoq sales trying to make up for...